HomeNewsRespiratoryCOPD

  • NICE advises restricted use of antibiotics for COPD

    • July 10, 2018
    • Posted by: Pharmascroll
    No Comments

    These draft recommendations come as NICE publishes draft antimicrobial prescribing guidance and a separate update to its 2010 clinical guideline on diagnosing and managing COPD in over 16s. The draft antimicrobial guidance recommends that antibiotics should be offered to people who have a severe flare up of symptoms, also known as a severe acute exacerbation. However other factors should

    read more

  • Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with COPD at ATS Conference

    • May 16, 2018
    • Posted by: Pharmascroll
    No Comments

    Bellerophon Therapeutics, a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from its Phase 2 study evaluating the use of INOpulse® in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) at the American Thoracic Society(ATS) 114th International Conference, on Monday, May 21, 2018, in San Diego, CA. This Phase 2 study

    read more

  • AstraZeneca’s Fasenra Fails in Phase III COPD Trial

    • May 11, 2018
    • Posted by: Pharmascroll
    No Comments

    GALATHEA Phase III trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD Second Phase III trial TERRANOVA is ongoing with results expected later this quarter AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in

    read more

  • Verona Pharma to Present Clinical Trial Data of RPL554 at ATS (American Thoracic Society 2018) Conference

    • May 9, 2018
    • Posted by: Pharmascroll
    No Comments

    Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present data from its chronic obstructive pulmonary disease (COPD) clinical trial program with lead product candidate, RPL554, at the American Thoracic Society International Conference (ATS) in San Diego, CA from May 18-23, 2018. RPL554 is a first-in-class, inhaled, dual inhibitor

    read more

  • Verona Pharma to Mark its Presence at BioEquity Europe 2018

    • May 5, 2018
    • Posted by: Pharmascroll
    No Comments

    Verona Pharma plc a clinical-stage bio-pharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Piers Morgan, Chief Financial Officer of Verona Pharma, will present at Bio€quity Europe 2018 to be held May 14-16, 2018 in Ghent, Belgium. Piers Morgan, Chief Financial Officer is scheduled to present Tuesday, May 15th at 5:20 PM CEST. About Verona Pharma plc Verona Pharma is a

    read more

  • Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

    • April 25, 2018
    • Posted by: Pharmascroll
    No Comments

      GlaxoSmithKline and Innoviva today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced

    read more

  • Novartis updates Launch Timeline for Advair Copy to 2019

    • April 22, 2018
    • Posted by: Pharmascroll
    No Comments

    Expected to hit the market by 2018, Advair generic copy from Novartis now has a revised timeline of 2019. Earlier in February, FDA turned back the probable generic from Novartis directing company to complete a a small bio-equivalence bridging study. Novartis CEO, Vasant Narasimhan while answering a question from an analyst during “Novartis First Quarter Conference Call” stated

    read more

  • GSK Appoints Senior Executive from Roche to Accelerate Pipeline Growth

    • April 20, 2018
    • Posted by: Pharmascroll
    No Comments

    GlaxoSmithKline plc (GSK) announced appointment  of Kevin Sin as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development. In this position, Kevin will play a critical role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients. Kevin will join GSK in

    read more

  • Trelegy Ellipta – IMPACT Study Shows Significant Benefits in COPD Patients

    • April 19, 2018
    • Posted by: Pharmascroll
    No Comments

      Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one of the biggest ever

    read more
SPEAK TO AN EXPERT